Merck  & Co.'s (MRK) potential $40 billion acquisition of Seagen (SGEN) is likely to be back in focus after the cancer drug ...

in a deal that could be worth roughly $40 billion or more. The companies are discussing a price for Seagen above $200 a share and are seeking to seal a deal on or before the announcement of Merck ...

Merck is reportedly eying cancer drug specialists Seagen as it looks to replace revenue from its Keytruda blockbuster, which loses patent exclusivity in 2028. Seagen (SGEN) - Get Seagen Inc ...

July 6 (Reuters) - Drugmaker Merck & Co (MRK.N) is in advanced talks to buy cancer-focused biotech company Seagen Inc (SGEN.O) in a deal that could be worth roughly $40 billion or more ...

Merck & Co . (NYSE:MRK) is close to agreeing to buy the biotechnology company Seagen (NASDAQ:SGEN) in a deal that can be worth about $40 billion, according to a report in the Wall Street Journal.

(Reuters) -Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported on ...

(Reuters) -Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported on ...